GO:0004962 endothelin receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004962 (endothelin receptor activity) is a molecular function defined as combining with endothelin and transmitting the signal across the membrane by activating an associated G-protein, promoting GDP-for-GTP exchange on the G-alpha subunit.
• The two canonical endothelin receptors are EDNRA (endothelin-A receptor) and EDNRB (endothelin-B receptor), both G-protein-coupled receptors with seven transmembrane domains.
• Endothelin receptor signalling is a validated drug target: the dual ETA/ETB antagonist bosentan and the selective ETA antagonist ambrisentan are approved for pulmonary arterial hypertension.
• Cryo-EM structures of endothelin receptors bound to endothelin-1 and G-proteins have revealed the molecular basis of ligand recognition and biased signalling.
• Endothelin receptor blockade has been explored in cancer, cardiovascular disease, and most recently in SARS-CoV-2-induced osteoarthritis [5,8].
• CRISPR knockout, point-mutation, knock-in, and overexpression cell models enable causal dissection of EDNRA/EDNRB signalling in disease [2,3].
Description
Endothelin receptor activity (GO:0004962) is the molecular function of binding an endothelin peptide and transducing that binding event across the plasma membrane by activating a heterotrimeric G-protein, thereby promoting exchange of GDP for GTP on the G-alpha subunit. This activity is mediated by two closely related G-protein-coupled receptors, EDNRA (endothelin-A receptor) and EDNRB (endothelin-B receptor), which together constitute the endothelin system. The endothelin system was originally identified as one of the most potent vasoconstrictor pathways in mammals, and it remains a paradigm for peptide hormone signalling through GPCRs [1,2]. For researchers, GO:0004962 matters because it sits at the intersection of cardiovascular physiology, cancer biology, and inflammatory disease. Pharmacological blockade of endothelin receptors is clinically established in pulmonary arterial hypertension, and endothelin receptor antagonists have been investigated in oncology and, more recently, in viral-arthritis models [2,5,8]. Understanding the precise molecular mechanism, the genes involved, and the experimental models available is therefore essential for anyone studying this pathway. This article integrates the QuickGO definition of GO:0004962 with verified PubMed literature to provide a research-grade overview of endothelin receptor activity, its structural basis, its regulation, its disease relevance, and the CRISPR-based methods used to interrogate it.
endothelin receptor activity At A Glance
| GO ID | GO:0004962 |
|---|---|
| GO term | endothelin receptor activity |
| Ontology | molecular_function |
| Synonym | endothelin-A receptor activity; endothelin-B receptor activity |
| Definition | Combining with endothelin and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. |
| Major function | Ligand-activated guanine nucleotide exchange on heterotrimeric G-proteins |
| Representative genes | EDNRA, EDNRB |
| Ligands | EDN1, EDN2, EDN3 |
| Cellular location | Plasma membrane |
| Pathway context | GPCR signalling; vasoconstriction; cell proliferation |
What Is GO:0004962?
In our own words, GO:0004962 describes the function of a receptor that (1) binds an endothelin peptide ligand, (2) undergoes a conformational change that enables it to act as a guanine nucleotide exchange factor for a heterotrimeric G-protein, and (3) thereby transmits a signal across the membrane by promoting GDP-to-GTP exchange on the G-alpha subunit. This is the defining molecular activity of EDNRA and EDNRB, and it is the upstream event that initiates all downstream endothelin signalling, including vasoconstriction, cell proliferation, and gene expression changes [2,3].
Why Is endothelin receptor activity Important in Cell Biology?
Endothelin receptor activity is important because it is the molecular entry point for one of the most potent vasoactive systems in human physiology and because it is a clinically validated drug target. The endothelin axis regulates vascular tone, cardiac function, and renal homeostasis, and its dysregulation is implicated in pulmonary arterial hypertension, cancer progression, and inflammatory joint disease [2,5,8]. Because the activity is mediated by two distinct receptors with overlapping but non-identical functions, understanding GO:0004962 at the molecular level is essential for designing selective antagonists and for interpreting genetic and pharmacological experiments [2,3].
• Endothelin receptor activity is the initiating step in endothelin signalling, a major vasoconstrictor pathway.
• EDNRA and EDNRB are both GPCRs, making GO:0004962 a model for peptide-activated GPCR mechanisms [2,3].
• Endothelin receptor antagonists are approved for pulmonary arterial hypertension.
• Endothelin receptor blockade has been studied in cancer, where the axis promotes proliferation and survival.
• Endothelin receptor antagonism has been explored in cardiovascular and renal disease.
• Atrasentan, a selective ETA antagonist, has been developed for prostate cancer and diabetic nephropathy.
• Endothelin receptor blockade mitigates SARS-CoV-2-induced osteoarthritis in preclinical models.
• Cryo-EM structures of endothelin receptors provide templates for structure-based drug design.
• The endothelin system is a paradigm for understanding biased agonism and G-protein coupling.
• CRISPR models of EDNRA/EDNRB enable causal testing of receptor function in disease.
What Happens During endothelin receptor activity?
Ligand binding and receptor activation
In simple terms: An endothelin peptide docks into the receptor, flipping the receptor into its active shape.
Endothelin receptor activity begins when an endothelin peptide (EDN1, EDN2, or EDN3) binds to the extracellular loops and transmembrane pocket of EDNRA or EDNRB. Structural studies using cryo-electron microscopy have shown that endothelin-1 engages the receptor through a two-step mechanism involving initial capture by extracellular loops followed by insertion of the peptide's C-terminal tail into the transmembrane binding pocket. This binding event stabilizes an active conformation of the receptor, which is the prerequisite for G-protein coupling.
G-protein coupling and nucleotide exchange
In simple terms: The activated receptor acts like a switch that tells the G-protein to swap its GDP for GTP.
Upon activation, the endothelin receptor engages a heterotrimeric G-protein complex composed of alpha, beta, and gamma subunits. The receptor acts as a guanine nucleotide exchange factor, promoting the release of GDP from the G-alpha subunit and its replacement by GTP. This GDP-for-GTP exchange is the defining catalytic event of GO:0004962 and is the point at which the extracellular signal is converted into an intracellular one [2,3].
G-alpha subunit dissociation and downstream signalling
In simple terms: Once GTP is bound, the G-protein splits into pieces that go on to trigger cellular responses.
GTP binding induces dissociation of the G-alpha subunit from the G-beta-gamma dimer. Both the GTP-bound G-alpha subunit and the free G-beta-gamma dimer can then modulate downstream effectors, including phospholipase C, adenylyl cyclase, and ion channels, depending on the receptor and cell type. This branching is the basis for the diverse physiological effects of endothelin, from smooth muscle contraction to gene expression changes [2,3].
Receptor desensitization and internalization
In simple terms: After signalling, the receptor is switched off and pulled inside the cell to stop the response.
Following sustained activation, endothelin receptors undergo phosphorylation by G-protein-coupled receptor kinases and recruit beta-arrestins, which uncouple the receptor from G-proteins and promote internalization. This desensitization mechanism is important for terminating the signal and for recycling or degrading the receptor. Dysregulation of this process can contribute to sustained endothelin signalling in disease.
Key Genes Involved in GO:0004962 endothelin receptor activity
The following genes encode the receptors, ligands, and downstream effectors that define endothelin receptor activity and its physiological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EDNRA | Endothelin-A receptor; binds EDN1 and EDN2 with high affinity | Primary mediator of vasoconstriction; target of selective antagonists |
| EDNRB | Endothelin-B receptor; binds all three endothelins | Mediates clearance and vasodilation; target of dual antagonists |
| EDN1 | Endothelin-1 peptide ligand | Most potent vasoconstrictor; biomarker in cardiovascular disease |
| EDN2 | Endothelin-2 peptide ligand | Roles in ovulation and cancer |
| EDN3 | Endothelin-3 peptide ligand | Critical for neural crest development |
| ECE1 | Endothelin-converting enzyme 1 | Generates mature endothelin peptides |
| ECE2 | Endothelin-converting enzyme 2 | Alternative processing enzyme |
| GNAQ | G-alpha q subunit | Couples EDNRA to phospholipase C |
| GNA11 | G-alpha 11 subunit | Couples endothelin receptors to calcium signalling |
| GNAI1 | G-alpha i subunit | Mediates inhibitory coupling to adenylyl cyclase |
| ARRB1 | Beta-arrestin 1 | Regulates receptor desensitization and internalization |
| ARRB2 | Beta-arrestin 2 | Regulates receptor trafficking and biased signalling |
| GRK2 | G-protein-coupled receptor kinase 2 | Phosphorylates activated endothelin receptors |
| PLCB1 | Phospholipase C beta 1 | Downstream effector of G-alpha q |
| RHOA | Ras homolog family member A | Mediates cytoskeletal and contractile responses |
| MAPK1 | Mitogen-activated protein kinase 1 | Transduces proliferative signals |
| MAPK3 | Mitogen-activated protein kinase 3 | Transduces proliferative signals |
| AKT1 | AKT serine/threonine kinase 1 | Survival signalling downstream of endothelin receptors |
How Is endothelin receptor activity Regulated?
Endothelin receptor activity is regulated at multiple levels. Ligand availability is controlled by endothelin-converting enzymes, which proteolytically generate mature endothelin peptides from inactive precursors. Receptor sensitivity is modulated by phosphorylation and beta-arrestin recruitment, which desensitize and internalize the receptor after activation. At the transcriptional level, EDNRA and EDNRB expression is influenced by hypoxia, cytokines, and growth factors, which can alter the cellular response to endothelin. Additionally, receptor heterodimerization and biased agonism can shape which G-protein pathways are engaged, adding further regulatory complexity.
endothelin receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EDNRA | Pulmonary arterial hypertension; vasoconstriction | EDNRA knockout or point-mutation endothelial cells |
| EDNRB | Pulmonary arterial hypertension; neural crest development | EDNRB knockout or knock-in reporter cells |
| EDN1 | Cardiovascular disease; cancer | EDN1 overexpression or knockout cell lines |
| EDNRA/EDNRB | SARS-CoV-2-induced osteoarthritis | Endothelin receptor blockade in chondrocyte models |
| EDNRA | Prostate cancer; diabetic nephropathy | Atrasentan-treated cancer cell lines |
Pulmonary arterial hypertension and cardiovascular disease
Endothelin receptor activity is a central driver of pulmonary arterial hypertension, where excessive endothelin signalling causes vasoconstriction and vascular remodelling. Endothelin receptor antagonists such as bosentan and ambrisentan are approved therapies for this condition, validating GO:0004962 as a drug target. In broader cardiovascular disease, endothelin receptor antagonism has been investigated for hypertension, heart failure, and renal disease.
Cancer
Endothelin receptor activity promotes proliferation, survival, and angiogenesis in several cancers, and endothelin receptor antagonism has been explored as an anticancer strategy. Atrasentan, a selective ETA antagonist, was developed for prostate cancer and diabetic nephropathy, illustrating the therapeutic interest in this pathway. The endothelin axis is therefore a candidate target for precision oncology approaches.
SARS-CoV-2-induced osteoarthritis
Recent work has shown that blockade of endothelin receptors mitigates SARS-CoV-2-induced osteoarthritis in preclinical models, linking endothelin receptor activity to viral inflammatory joint disease. This finding expands the disease relevance of GO:0004962 beyond classical cardiovascular indications and highlights its role in inflammation and tissue remodelling.
From endothelin receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does EDNRA mediate vasoconstriction? | EDNRA knockout endothelial or smooth muscle cells |
| Does EDNRB mediate endothelin clearance? | EDNRB knockout cell lines |
| Which G-protein couples to EDNRA? | Point-mutated EDNRA knock-in cells |
| How does endothelin-1 binding change receptor conformation? | Tagged knock-in EDNRA for structural studies |
| Does overexpression of EDN1 drive proliferation? | EDN1 overexpression cell models |
| Can endothelin receptor blockade prevent osteoarthritis? | Receptor antagonist-treated chondrocyte models |
How to Study the endothelin receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-EM | Receptor-ligand-G-protein structure | Mechanistic studies of endothelin receptor activation |
| Radioligand binding | Ligand affinity and receptor density | Characterizing EDNRA/EDNRB antagonists |
| GTP-gamma-S binding | G-protein activation | Measuring receptor coupling efficiency |
| Calcium mobilization | Downstream signalling | Functional screening of receptor variants |
| RNA-seq | Transcriptional changes | Identifying endothelin-regulated genes |
| Proteomics | Protein expression and modifications | Mapping downstream effectors |
| CRISPR knockout | Loss-of-function phenotype | Testing causal role of EDNRA/EDNRB |
| CRISPR knock-in | Tagged or mutant receptor expression | Structural and trafficking studies |
Structural biology (cryo-EM and X-ray crystallography)
Cryo-electron microscopy has been used to determine structures of endothelin receptors bound to endothelin-1 and G-proteins, revealing the molecular basis of ligand recognition and receptor activation. These structures provide templates for understanding how GO:0004962 is executed at the atomic level and for structure-based drug design.
Pharmacological and signalling assays
Endothelin receptor activity is commonly measured using radioligand binding assays, GTP-gamma-S binding assays, and calcium mobilization assays. These methods quantify ligand affinity, G-protein activation, and downstream second messenger production, and they are used to characterize receptor antagonists.
CRISPR-based genetic models
CRISPR knockout, point-mutation, knock-in, and overexpression cell models enable causal testing of EDNRA and EDNRB function. These models can be combined with signalling assays to determine how specific residues or domains contribute to endothelin receptor activity [2,3].
Transcriptomics and proteomics
RNA sequencing and proteomics can be used to profile downstream gene expression and protein changes following endothelin receptor activation or blockade. These approaches help identify the broader network of effectors and biomarkers associated with GO:0004962.
How CRISPR Can Be Used to Study GO:0004962 endothelin receptor activity
Knockout
CRISPR knockout of EDNRA or EDNRB in cell models abolishes endothelin receptor activity, allowing researchers to test the contribution of each receptor to downstream signalling and disease phenotypes. Knockout models are particularly useful for distinguishing ETA from ETB receptor functions in vasoconstriction, clearance, and proliferation.
Point Mutation
Point mutations introduced by CRISPR base editing or homology-directed repair can be used to dissect the residues required for ligand binding, G-protein coupling, or desensitization in EDNRA and EDNRB [2,3]. Such models help map structure-function relationships within GO:0004962.
Knock-in
Knock-in of tagged or fluorescently labeled endothelin receptors enables real-time imaging of receptor trafficking, internalization, and localization in live cells. Knock-in models can also be used to express disease-associated receptor variants at endogenous levels.
Overexpression
Overexpression of EDNRA, EDNRB, or their ligands (EDN1, EDN2, EDN3) in cell models can amplify endothelin receptor activity and reveal gain-of-function phenotypes, such as enhanced proliferation or survival. Overexpression models are useful for screening antagonists and for studying downstream signalling networks.
How EDITGENE Supports endothelin receptor activity Research
Researchers studying endothelin receptor activity-related genes often need to determine whether a candidate gene is causally involved in a given phenotype, and CRISPR-based cell models provide a rigorous way to test this. EDITGENE offers a suite of services designed to accelerate such studies, from knockout and point-mutation models to knock-in reporters and overexpression lines.
Contact EDITGENE today to design your custom CRISPR model for endothelin receptor activity research.
Frequently Asked Questions About endothelin receptor activity
What is endothelin receptor activity?
Endothelin receptor activity (GO:0004962) is the molecular function of binding an endothelin peptide and transmitting the signal across the membrane by activating an associated G-protein, promoting GDP-for-GTP exchange on the G-alpha subunit.
What genes are involved in endothelin receptor activity?
The core genes are EDNRA (endothelin-A receptor) and EDNRB (endothelin-B receptor), with ligands EDN1, EDN2, and EDN3, and processing enzyme ECE1.
What is the GO ID for endothelin receptor activity?
The GO ID is GO:0004962, and it belongs to the molecular_function ontology.
What are the synonyms for endothelin receptor activity?
The synonyms are endothelin-A receptor activity and endothelin-B receptor activity.
How does endothelin receptor activity work?
An endothelin peptide binds EDNRA or EDNRB, stabilizing an active receptor conformation that couples to a heterotrimeric G-protein and promotes GDP-to-GTP exchange on the G-alpha subunit [2,3].
What diseases are linked to endothelin receptor activity?
It is linked to pulmonary arterial hypertension, cardiovascular disease, cancer, and SARS-CoV-2-induced osteoarthritis [2,5,8].
What drugs target endothelin receptor activity?
Bosentan and ambrisentan are approved endothelin receptor antagonists for pulmonary arterial hypertension, and atrasentan is a selective ETA antagonist studied in cancer [2,7].
How can I study endothelin receptor activity in the lab?
Common methods include radioligand binding, GTP-gamma-S binding, calcium mobilization assays, cryo-EM, and CRISPR knockout or knock-in cell models [2,3].
What is the structure of endothelin receptors?
EDNRA and EDNRB are seven-transmembrane GPCRs, and cryo-EM structures have revealed how endothelin-1 binds and activates them.
Can CRISPR be used to study endothelin receptor activity?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of EDNRA and EDNRB function [2,3].
Conclusion
Endothelin receptor activity (GO:0004962) is a well-defined molecular function that initiates one of the most potent vasoactive signalling pathways in human biology. Its two receptors, EDNRA and EDNRB, are validated drug targets in pulmonary arterial hypertension and are under investigation in cancer and inflammatory disease [2,5,8]. Structural and pharmacological studies have provided a detailed mechanistic understanding of how endothelin binding leads to G-protein activation. For researchers, CRISPR-based cell models offer a powerful way to test the causal role of endothelin receptor genes and to dissect the molecular determinants of receptor function [2,3]. EDITGENE provides a comprehensive suite of CRISPR services to support such studies, from knockout and point-mutation models to knock-in reporters and overexpression lines.
References
- 1. Emoto N et al.. 2014. Endothelin XIII.. Life Sci 118(2):47-50 PMID: 25264369
- 2. Davenport AP et al.. 2016. Endothelin.. Pharmacol Rev 68(2):357-418 PMID: 26956245
- 3. Shihoya W et al.. 2023. Structural insights into endothelin receptor signalling.. J Biochem 174(4):317-325 PMID: 37491722
- 5. Bhalla A et al.. 2009. Endothelin receptor antagonism and cancer.. Eur J Clin Invest 39 Suppl 2:74-7 PMID: 19335749
- 6. Benigni A et al.. 1999. Endothelin antagonists.. Lancet 353(9147):133-8 PMID: 10023915
- 7. Norman P. 2002. Atrasentan Abbott.. Curr Opin Investig Drugs 3(8):1240-8 PMID: 12211423
- 8. Au MT et al.. 2024. Blockade of endothelin receptors mitigates SARS-CoV-2-induced osteoarthritis.. Nat Microbiol 9(10):2538-2552 PMID: 39261580
